Subscribe
Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.
Dermatophytoma: A Diagnosis That You Do Not Want to Miss
Medical-Toxicological Knowledge Gaps Pose Challenges Despite Advances in Tattooing
Soligenix Announces Publication of Promising Comparative Data for HyBryte Synthetic Hypericin for CTCL
Hyper- and Hypopigmentation and Burning Among Most Patient-Reported Adverse Effects During Breast Cancer Treatment
Joseph Gorelick, MSN, FNP-C
Brad P. Glick, DO, MPH, FAAD
Hilary Baldwin; Neal Bhatia, MD
Tina Bhutani, MD
June 17-19, 2026
Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD
Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc
Andrew Alexis, MD, MPH; Leon Kircik, MD
Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD
Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD